Evidence map›Paper›PMID 38769156›Full record

ArticleThe Journal of antibiotics2024

Antidermatophyte activity and PK/PD of ME1111 in a guinea pig model of tinea corporis.

Naomi Takei-Masuda, Yu Nagira, Natsuki Kubota-Ishida, Tsubasa Chikada, Yuji Tabata, Kazunori Maebashi

Abstract read
PubMed Publisher
In one paragraph

Article in The Journal of antibiotics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Naomi Takei-MasudaMeiji Seika Pharma Co., Ltd., Tokyo, Japan. naomi.masuda@meiji.com.
Yu NagiraMeiji Seika Pharma Co., Ltd., Tokyo, Japan.
Natsuki Kubota-IshidaMeiji Seika Pharma Co., Ltd., Tokyo, Japan.
Tsubasa ChikadaMeiji Seika Pharma Co., Ltd., Tokyo, Japan.
Yuji TabataMeiji Seika Pharma Co., Ltd., Tokyo, Japan.
Kazunori MaebashiMeiji Seika Pharma Co., Ltd., Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Onychomycosis, a superficial fungal infection of the nails, is prevalent in many areas of the world. Topical agents for onychomycosis need to reach the subungual layer and nail bed to exert antifungal activity in the presence of keratin, the major component of the nail. It is difficult to evaluate the efficacy and pharmacodynamics of topical agents for onychomycosis in a non-clinical evaluation system. No consistent animal model has yet been established to predict the efficacy of topical agents for onychomycosis. In this study, we evaluated the pharmacokinetics and pharmacodynamics of ME1111 in a guinea pig model of tinea corporis designed to predict the efficacy of topical medication for onychomycosis in the vicinity of the nail bed. Trichophyton mentagrophytes TIMM1189 was infected on the back skin of guinea pigs, and ME1111 solution (5%, 10%, or 15%) was administered topically, once daily for 14 consecutive days. Following the completion of dosing, segments of skin from the site of infection were excised and cultured. The concentration of ME1111 in the back skin of guinea pigs increased with formulation concentration and correlated with mycological efficacy. We revealed the concentration required for ME1111 to be effective at the site of infection. Further analysis is needed to predict the efficacy of topical agents for onychomycosis by analyzing the relationship between PK/PD around the nail bed and factors such as subungual penetration and permeability.

Indexed as

Antifungal AgentsDisease Models, AnimalOnychomycosisTineaAdministration, TopicalAnimalsArthrodermataceaeGuinea PigsMaleNailsPhenolsPyrazolesSkin2-(3,5-dimethyl-1H-pyrazol-1-yl)-5-methylphenolAntifungal AgentsPhenolsPyrazoles

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.